Evidence map›Paper›PMID 32710432›Full record

ArticleInternational journal of hematology2020

Living-donor liver transplantation providing an adequate chemotherapy for a pediatric patient with anaplastic large cell lymphoma complicated with liver failure due to the aggravation of biliary hepatopathy by secondary hemophagocytic lymphohistiocytosis.

Kenichi Sakamoto, Tomoo Osumi, Satoshi Yoshimura, Seiichi Shimizu, Motohiro Kato, Daisuke Tomizawa, Akinari Fukuda, Seisuke Sakamoto, Noriyuki Nakano, Takako Yoshioka and 6 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Secondary hemophagocytic lymphohistiocytosis in children (Review).Experimental and therapeutic medicine · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kenichi SakamotoChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. sakamoto-k@ncchd.go.jp.ORCID http://orcid.org/0000-0003-1499-538X
Tomoo OsumiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Satoshi YoshimuraChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Seiichi ShimizuOrgan Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Motohiro KatoChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Daisuke TomizawaChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Akinari FukudaOrgan Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Seisuke SakamotoOrgan Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Noriyuki NakanoDepartment of Pathology, National Center for Child Health and Development, Tokyo, Japan.
Takako YoshiokaDepartment of Pathology, National Center for Child Health and Development, Tokyo, Japan.
Osamu MiyazakiDepartment of Radiology, National Center for Child Health and Development, Tokyo, Japan.
Syunsuke NosakaDepartment of Radiology, National Center for Child Health and Development, Tokyo, Japan.
Takao DeguchiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Tokyo, Japan.
Mureo KasaharaOrgan Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Kimikazu MatsumotoChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic large cell lymphoma (ALCL) accounts for 10-15% of childhood non-Hodgkin lymphoma cases; it is generally chemo-sensitive and is one of the most curable pediatric cancers. We report here a case of pediatric ALCL complicated with acute liver failure due to the aggravation of pre-existing biliary hepatopathy by lymphoma-associated hemophagocytic lymphohistiocytosis (HLH). Although the initial treatment response against ALCL was very good, poor and irreversible liver function due to biliary cirrhosis worsening by lymphoma-associated HLH prevented the patient from receiving further consolidation chemotherapies. To make matters worse, his condition was accompanied with intrahepatic fungal pseudoaneurysm and invasive fungal infection. Thus, we decided to perform an urgent living-donor liver transplantation from his father to correct the patient's liver function and make it possible to proceed with further ALCL therapy. After the living-donor liver transplantation, the patient successfully received consolidation therapy with brentuximab vedotin. To our knowledge, this may be an early reported case of a pediatric patient undergoing liver transplantation during treatment for ALCL. In most patients with HLH-associated ALCL, liver function improves when ALCL is controlled. However, acute liver failure is occasionally observed in HLH cases with pre-existing liver dysfunction. In such cases, liver transplantation should be considered to correct liver dysfunctions if the disease control of HLH is satisfactory.

Indexed as

Liver TransplantationLiving DonorsBrentuximab VedotinChildCombined Modality TherapyConsolidation ChemotherapyDisease ProgressionHumansLiver Cirrhosis, BiliaryLiver FailureLymphohistiocytosis, HemophagocyticLymphoma, Large-Cell, AnaplasticMaleTreatment OutcomeBrentuximab VedotinAnaplastic large cell lymphomaHepatic failureLiving-donor liver transplantationPediatric

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.